… Participants were either naïve to androgen therapy or were … normal range (based on phase
II clinical results) and estimating … dose) approach coupled with a novel formulation met FDA …

… Several studies have demonstrated the effects of testosterone … More recent phases II and
III pharmacokinetic studies have … This component combination provides a prolonged IM …

… , a novel androgen axis inhibitor, to androgen deprivation … Phase II study of single-agent
orteronel (TAK-700) in patients … and castrate levels of testosterone: Recommendations of the …

… (DHT), an androgen formed by testosterone (T) reduction … analysis of a multicenter,
open-label, dose-ranging phase 3 … Nonetheless, it appears that the intramuscular T enanthate or …

… novel transdermal gel containing testosterone and segesterone acetate (Nestorone), a progestin.
An ongoing phase II study … Intramuscular testosterone undecanoate and norethisterone …

… (CRPC) receiving androgen deprivation therapy and for … This multicenter, open-label, phase
Ib drug–drug interaction … despite surgical or medical castration (testosterone levels of <50 ng/…

… , and novel therapies including nasal testosterone, aromatase … further study found that weekly
intramuscular 200 mg testosterone … These findings are supported by a phase II multicentre, …

… hypogonadism needing continued androgen therapy, the dosage of IM testosterone enanthate
or … Daily oral administration of the novel androgen 11beta-MNTDC markedly suppresses …

… -carbon long androgen ester derivative of testosterone that comes … Unique to the intramuscular
(IM) injection of testosterone … The initial, multicenter, open-label clinical trial investigated …

… Patients had chemotherapy-naïve mCRPC with progression on ≥ 1 androgen receptor …
This was a phase Ib/II multicenter, open-label study of ribociclib in combination with docetaxel …